metricas
covid
Buscar en
Archivos de la Sociedad Española de Oftalmología (English Edition)
Toda la web
Inicio Archivos de la Sociedad Española de Oftalmología (English Edition) Brolucizumab after failure of aflibercept with photodynamic therapy in polypoida...
Journal Information
Vol. 98. Issue 12.
Pages 713-717 (December 2023)
Share
Share
Download PDF
More article options
Vol. 98. Issue 12.
Pages 713-717 (December 2023)
Short communication
Brolucizumab after failure of aflibercept with photodynamic therapy in polypoidal choroidal vasculopathy: A case report
Brolucizumab tras fracaso de aflibercept con terapia fotodinámica en vasculopatía coroidea polipoidea: reporte de un caso
P.H. Yuana, H.M. Khana, F.A.G. Sumitab,c,
Corresponding author
fernando-sumita@hotmail.com

Corresponding author.
, M.L. Ribeiro Monteiroc, R.C. Pretic, E.V. Navajasb
a Faculty of Medicine, University of British Columbia, Vancouver (British Columbia), Canada
b Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver (British Columbia), Canada
c Division of Ophthalmology, University of São Paulo Medical School, São Paulo, Brazil
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Abstract

We describe one case of polypoidal choroidal vasculopathy with persistent subretinal fluid despite multiple treatment with intravitreal Bevacizumab, Ranibizumab and Aflibercept, as well as Aflibercept associated with photodynamic therapy. The patient reached complete resolution after intravitreal Brolucizumab injection, but experienced recurrence of subretinal fluid 12 weeks after discontinuation. Brolucizumab might be an option in treating subretinal fluid after failure of other anti-VEGF agents associated with photodynamic therapy.

Keywords:
Choroidal polypoidal vasculopathy
Brolucizumab
Subretinal fluid
Photodynamic therapy
Age-related macular degeneration
Resumen

Describimos un caso de vasculopatía coroidea polipoidea con líquido subretiniano persistente a pesar de múltiples tratamientos intravítreos con bevacizumab, ranibizumab y aflibercept, así como aflibercept asociado a terapia fotodinámica. El paciente alcanzó la resolución completa después de la inyección intravítrea de brolucizumab, pero experimentó una recurrencia del líquido subretiniano 12 semanas después de la suspensión. Brolucizumab podría ser una opción para tratar el líquido subretiniano después del fracaso de otros agentes anti-VEGF asociados con la terapia fotodinámica.

Palabras clave:
Vasculopatía coroidea polipoidea
Brolucizumab
Líquido subretiniano
Terapia fotodinámica
Degeneración macular asociada a la edad

Article

These are the options to access the full texts of the publication Archivos de la Sociedad Española de Oftalmología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Archivos de la Sociedad Española de Oftalmología (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos